Compare Biogen Inc (BIIB) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Biogen Inc trades at $197.27 (market cap $28.34B), while iShares 3 7 Year Treasury Bond ETF trades at $117.04. The key difference: Biogen Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | IEI | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Fixed Income |
52-Week High | $216.63 | $120.72 |
52-Week Low | $122.68 | $116.45 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.45, down 0.27% on the day. The technical outlook is bearish, with moving averages signaling a downtrend, though oscillators are neutral. Recent news highlights competition from Vanguard bond ETFs on yield and cost, while broader bond market inflows surge amid Fed policy uncertainty. The fund maintains regular dividend distributions, with recent payments around $0.36-$0.37 per share.
The outlook for IEI is cautious due to bearish technicals and competitive pressure from higher-yielding alternatives. Rising interest rate expectations pose a headwind, but its Treasury focus offers lower volatility. Key risks include Fed policy shifts and inflation persistence. Investors seeking intermediate-term government bond exposure may find stability, but yield hunters might prefer corporate or broader market ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
